Document Detail


Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats.
MedLine Citation:
PMID:  3086417     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tissue-type plasminogen activator is a new thrombolytic agent that dissolves intravascular thrombi in coronary and peripheral vessels with less pronounced systemic lysis than that produced by streptokinase. Plasminogen activator was shown to induce reperfusion, and to salvage ischemic myocardium, by lysing experimentally induced coronary artery thrombi. The effect of a melanoma cell-derived tissue-type plasminogen activator was studied in cat myocardium rendered ischemic by coronary artery ligation for 2 hours and reperfused for another 4 hours. Plasminogen activator was infused at a rate of 500 IU X kg-1 X min-1 for the first 30 minutes of reperfusion. The marked increase in plasma creatine kinase activity during reperfusion was significantly lower in plasminogen activator-treated cats at 4, 5 and 6 hours, with 7.7 +/- 1.5 X 10(-3) IU X mg protein-1 (n = 8) in the plasminogen activator group versus 17.8 +/- 3.5 X 10(-3) IU X mg protein-1 (n = 7) in the vehicle group at 6 hours (mean +/- SEM). The area at risk in the two ischemic groups was not different, being 14.6 +/- 1.5 and 16.6 +/- 1.4% of total left ventricular mass for the treated and untreated groups, respectively. However, the mass of necrotic tissue determined histochemically was significantly lower in the plasminogen activator-treated group, accounting for 29.5 +/- 3.9% of the area at risk compared with 46.8 +/- 4.2% of area at risk in cats receiving only the vehicle (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
H Darius; A Yanagisawa; M E Brezinski; C E Hock; A M Lefer
Related Documents :
25382137 - The clinical challenge of preventing sudden cardiac death immediately after acute st-el...
8797147 - Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occ...
3995707 - Factors that determine recovery of left ventricular function after thrombolysis in pati...
9344637 - Effects of supplementation with iloprost on the cardioprotection by bw755c (a dual inhi...
7588897 - Comparison and combination of late potentials and spectral turbulence analysis to predi...
224857 - Myocardial extraction of cyclic amp during pacing-induced angina.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  8     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1986 Jul 
Date Detail:
Created Date:  1986-07-18     Completed Date:  1986-07-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  125-31     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cats
Coronary Disease / blood,  drug therapy*,  physiopathology
Coronary Vessels / drug effects,  physiopathology
Creatine Kinase / blood
Electrocardiography
Fibrinogen / analysis
Hemodynamics / drug effects
Myocardium / pathology
Organ Size
Tissue Plasminogen Activator / therapeutic use*
Grant Support
ID/Acronym/Agency:
HL-25575/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
9001-32-5/Fibrinogen; EC 2.7.3.2/Creatine Kinase; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen...
Next Document:  Development of an iron checklist to guide food intake.